Eicosanoids and the vascular endothelium

Handbook of Experimental Pharmacology

Volumn 176, Issue PART1, 2006, Pages 189-211

  Egan, K ^a   Fitzgerald, G A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cyclooxygenase; Endothelium; Prostacyclin; Thromboxane; Vascular

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; ISOMERASE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN ISOMERASES; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; PTGIR PROTEIN, HUMAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR;

ANIMAL; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HUMAN; METABOLISM; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; CEREBROVASCULAR ACCIDENT; CYCLOOXYGENASE 2 INHIBITORS; EICOSANOIDS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GASTROINTESTINAL HEMORRHAGE; HEART DISEASES; HUMANS; ISOMERASES; PROSTAGLANDIN D2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOXANE A2;

EID: 84884527707     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-32967-6_6     Document Type: Article

References (149)

1. Adderley SR, Fitzgerald DJ (1999) Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274:5038-5046
2. Ali S, Davis MG, Becker MW, et al (1993) Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 268:17397-17403
3. Antithrombotic Trialists, Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
4. AshtonAW,Ware JA(2004)ThromboxaneA2receptor signaling inhibits vascularendothelial growth factor-induced endothelial cell differentiation and migration. Circ Res 95:372-379
5. Audoly LP, Tilley SL, Goulet J, et al (1999) Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. Am J Physiol 277:H924-H930
6. Audoly LP, Rocca B, Fabre JE, et al (2000) Cardiovascular responses to the isoprostanes iPF2alpha-III and iPE2-III are mediated via the thromboxane A2 receptor in vivo. Circulation 101:2833-2840
7. Austin SA, FitzGerald GA (1999) Not a mouse stirring: deletion of the EP2 and love's labor's lost. J Clin Invest 103:1481-1482
8. Bao Y, Pucci ML, Chan BS, et al (2002) Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 282:F1103-F1110
9. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295:1420-1427
10. Bell-Parikh C, Ide T, Lawson JA, et al (2003) Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 112:945-955
11. Bhagwat SS, Hamann PR, Still WC, et al (1985) Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature 315:511-513
12. Boie Y, Rushmore TH, Darmon-Goodwin A, et al (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 1994 269:12173-12178
13. Bombardier C, Laine L, Reicin A, et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528
14. Brash AR, Jackson EK, Saggese CA, et al (1983) Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 226:78-87
15. Breyer RM, Bagdassarian CK, Myers SA, et al (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661-690
16. Burke A, Smyth EM, FitzGerald GA (2005) Analgesic-anti-pyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Brunton LL, Lazo JS, Parker KL, et al (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, 673-715
17. Capone M,Tacconelli S, Sciulli MG, et al (2004)Clinical pharmacology of platelet,monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109:1468-1471
18. Capone M, Sciulli MG, Tacconelli S, et al (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45:1295-1301
19. Catella F, Healy D, Lawson JA, et al (1986) 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A 83:5861-5865
20. Catella-Lawson F, McAdam B, Morrison BW, et al (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289:735-741
21. Catella-Lawson F, Reilly MP, Kapoor SC, et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809-1817
22. Cayatte AJ, Du Y, Oliver-Krasinski J, et al (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728
23. Cheng Y, Austin SC, Rocca B, et al (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541
24. Cheng Y,Wang M, Yu Y, Lawson J, Funk C, FitzGerald GA (2006) Cyclooxygenases, microsomal prostaglandind E synthase-1 and cardiovascular fcunction. J Clin Invest 116:1391-1399
25. Cipollone F, Rocca B, Patrono C (2004) Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24:246-255
26. Clarke RJ, Mayo G, Price P, et al (1991) Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137-1141
27. Cok SJ, Acton SJ, Morrison AR (2003) The proximal region of the 3′-untranslated region of cyclooxygenase-2 is recognized by amultimeric protein complex containingHuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoproteinU. J Biol Chem278:36157-36162
28. Connolly E, Bouchier-Hayes DJ, Kaye E, et al (2002) Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther 300:393-398
29. Dixon DA (2004) Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 10:635-646
30. Dogne JM,HansonJ,de Leval X, et al (2004)Newdevelopments onthromboxanemodulators. Mini Rev Med Chem 4:649-657
31. DornGW, Sens D, Chaikhouni A, et al (1987) Cultured human vascular smoothmuscle cells with functional thromboxane A2 receptors: measurement of U46619-induced 45calcium efflux. Circ Res 60:952-956
32. Dowd NP, Scully M, Adderley SR, et al (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108:585-590
33. Egan KM, Lawson JA, Fries S, et al (2004) COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306:1954-1957
34. EganKM,Wang M, LucittMB, et al (2005)Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111:334-342
35. Evangelista V,Manarini S, DiSanto A, Capone ML, Riciotti E, et al (2006) De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 98:593-595
36. Fabre JE, Nguyen M,Athirakul K, et al (2001)Activation of themurine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 107:603-610
37. FitzgeraldDJ, EntmanSS,Mulloy K, et al (1987) Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation 75:956-963
38. Fitzgerald DJ, Rocki W, Murray R, et al (1990) Thromboxane A2 synthesis in pregnancyinduced hypertension. Lancet 335:751-754
39. FitzGerald GA (1991)Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68:11B-15B
40. FitzGerald GA (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 11:879-890
41. FitzGerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711
42. FitzGerald GA, Loll P (2001) COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 107:1335-1337
43. FitzGerald GA, PatronoC(2001) The coxibs, selective inhibitors of cyclooxygenase-2.NEngl J Med 345:433-442
44. FitzGerald GA, Friedman LA, Miyamori I, et al (1979) A double blind placebo controlled crossover study of prostacyclin in man. Life Sci 25:665-672
45. FitzGerald GA, Brash AR, Falardeau P, et al (1981) Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 68:1272-1276
46. FitzGerald GA Pedersen AK, Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67:1174-1177
47. Fitzpatrick FA (2004) Cyclooxygenase enzymes: regulation and function. Curr Pharm Des 10:577-588
48. Fleming EF, Athirakul K, Oliverio MI, et al (1998) Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. Am J Physiol 275:F955-F961
49. Francois H, Atirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, FitzGerald GA, Koller BH, Coffman TC (2005) Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2:201-207
50. Fujino T, Yuhki K, Yamada T, et al (2002) Effects of the prostanoids on the proliferation or hypertrophy of culturedmurine aortic smoothmuscle cells. Br J Pharmacol 136:530-539
51. Fujino T, Nakagawa N, Yuhki K, et al (2004) Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 114:805-812
52. Funk CD, Funk LB, Kennedy ME, et al (1991) Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. Faseb J 5:2304-2312
53. Garavito RM, Picot D, Loll PJ (1995) The 3.1 A X-ray crystal structure of the integral membrane enzyme prostaglandin H2 synthase-1. Adv Prostaglandin Thromboxane Leukot Res 23:99-103
54. Garcia-Rodriguez LA,Varas-Lorenzo C,Maguire A, et al (2004)Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109:3000-3006
55. Gerritsen ME (1987) Eicosanoid production by the coronary microvascular endothelium. Fed Proc 46:47-53
56. Gibbs JS, Broberg CS, Gatzoulis MA (2004) Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities. Int J Cardiol 97 Suppl 1:7-10
57. GrosserT, Fries S, FitzGeraldGA(2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4-15
58. Gryglewski RJ, Moncada S, Palmer RM (1986) Bioassay of prostacyclin and endotheliumderived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 87:685-694
59. Habib A, FitzGerald GA, Maclouf J (1999) Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 274:2645-2651
60. Hajjar D, Weksler BB, Falcone DJ, et al (1982) Prostacyclin modulates cholesteryl ester hydrolytic activity by its effect on cyclic adenosine monophosphate in rabbit aortic smooth muscle cells. J Clin Invest 70:479-488
61. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72:2994-2998
62. Hanson J, Rolin S, Reynaud D, et al (2005) In vitro and in vivo pharmacological characterization of BM-613 [N-n-Pentyl-N'-[2-(4′- methylphenylamino)-5-nitrobenzenesulfonyl] urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J Pharmacol Exp Ther 313:293-301
63. Hashimoto K, Graham BS, Geraci MW, et al (2004) Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. JVirol 78:10303-10309
64. Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147-166
65. Hennekens C, Schror K,Weisman S, et al (2004) Terms and conditions: semantic complexity and aspirin resistance. Circulation 110:1706-1708
66. Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299:125-140
67. Hirata M, Hayashi Y, Ushikubi F, et al (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349:617-620
68. Hirata T, Ushikubi F, Kakizuka A, et al (1996) Two thromboxane A2 receptor isoforms in humanplatelets.Opposite coupling to adenylyl cyclasewith different sensitivity to Arg60 to Leu mutation. J Clin Invest 97:949-956
69. Honda T, Segi-Nishida E, Miyachi Y, Narumiya S (2006) Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammationinmouse collageninduced arthritis. J Exp Med 203:325-335
70. Iniguez MA, Pablos JL, Carreira PE, et al (1998) Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br J Rheumatol 37:773-778
71. Ishizuka T, Matsui T, Kurita A, et al (2003) Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur J Pharmacol 468:27-35
72. Ishizuka T, Matsui T, Okamoto Yet al (2004) Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor. Cardiovasc Drug Rev 22:71-90
73. Jadhav V, Jabre A, Lin SZ, et al (2004) EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab 24:1305-1316
74. Kabashima K, Murata T, Tanaka H, et al (2003) Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 4:694-701
75. Kobayashi T, Tahara Y,MatsumotoM, et al (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114:784-794
76. Kothapalli D, Fuki I, Ali K, et al (2004) Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest 113:609-618
77. Kunapuli P, Lawson JA, Rokach J, et al (1997) Functional characterization of the ocular PGF2alpha receptor. Activation by the isoprostane, 12-iso-PGF2alpha. J Biol Chem 272:27147-27154
78. Lawson JA, Brash AR, Doran J, et al (1985)Measurement of urinary 2,3-dinor-thromboxane B2 and thromboxane B2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative-ion chemical ionization mass spectrometry. Anal Biochem 150:463-470
79. Leslie CC (1997) Properties and regulation of cytosolic phospholipase A2. J Biol Chem 272:16709-16712
80. Li R, Mouillesseaux KP, Montoya D, Cruz D, Gharavi N, Dun M, Koroniak L, Berliner JA (2006) Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC. Circ Res 98:642-650
81. Lim H, Dey SK (2002) A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 143:3207-3210
82. Lin LL, Lin AY, DeWitt DL (1992) Interleukin-1 alpha induces the accumulation of cytosolic phospholipase A2 and the release of prostaglandin E2 in human fibroblasts. J Biol Chem 267:23451-23454
83. Loll PJ, Picot D, Garavito RM (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2:637-643
84. Marnett LJ, Rowlinson SW, Goodwin DC, et al (1999) Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 274:22903-22906
85. Mason PJ, Freedman JE, Jacobs AK (2004) Aspirin resistance: current concepts. Rev Cardiovasc Med 5:156-163
86. McAdam B, Catella-Lawson F,Mardini IA, et al (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96:272-277
87. Minami T, Nakano H, Kobayashi T, et al (2001) Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br J Pharmacol 133:438-444
88. Moncada S, Vane JR (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293-331
89. Moncada S, Gryglewski R, Bunting S, et al (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665
90. Moncada S, Vane JR, Whittle BJ (1977) Relative potency of prostacyclin, prostaglandin E1 and D2 as inhibitors of platelet aggregation in several species. J Physiol 273:2P-4P
91. Morrow JD (2006) The isoprostanes-unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Des 12:895-902
92. Murakami M, Naraba H, Tanioka T, et al (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275:32783-32792
93. Murata T, Ushikubi F, Matsuoka T, et al (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682
94. Murphey LJ, Williams MK, Sanchez SC, et al (2004) Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 334:266-275
95. Nagata K, Hirai H (2003) The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 69:169-177
96. NambaT, SugimotoY,HirataM,et al (1992)Mouse thromboxaneA2receptor: cDNAcloning, expression and northern blot analysis. Biochem Biophys Res Commun 184:1197-1203
97. Namba T, Oida H, Sugimoto Y, et al (1994) cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 269:9986-9992
98. Narumiya S, FitzGerald GA (2001) Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108:25-30
99. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193-1226
100. Needleman P,Moncada S, Bunting S, et al (1976) Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261:558-560
101. Nguyen M, Camenisch T, Snouwaert JN, et al (1997) The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 390:78-81
102. Nusing RM,Hirata M,KakizukaA, et al (1993) Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J Biol Chem 268:25253-25259
103. Oka T, Oka K, Kobayashi T, et al (2003) Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. J Physiol 551:945-954
104. Pakala R,Willerson JT, Benedict CR, et al (1997) Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96:2280-2286
105. Patrignani P (2003) Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 110:281-286
106. PatronoC,CollerB, FitzGeraldGA,et al (2004) Platelet-active drugs: the relationshipsamong dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:234S-264S
107. PatschekeH(1985) Thromboxane synthase inhibition potentiateswashed platelet activation by endogenous and exogenous arachidonic acid. Biochem Pharmacol 1985 34:1151-1156
108. Pedersen AK, FitzGeraldGA(1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311:1206-1211
109. Physician's Health Study (1989) Aspirin and primary prevention of coronary heart disease. N Engl J Med 321:1825-1828
110. Picot D, Loll PJ, Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994 367:243-249
111. Pini B,Grosser T, Lawson JA, et al (2005) Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol 25:315-320
112. Pratico D, Cyrus T, Li H, et al (2000) Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96:3823-3826
113. PraticoD, Cheng Y, FitzGerald GA (2000) TP or not TP: primarymediators in a close runoff? Arterioscler Thromb Vasc Biol 20:1695-1698
114. Pratico D, Rokach J, Lawson J, et al (2004) F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids 128:165-171
115. Ridker PM, Cook NR, Lee IM, et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293-1304
116. Robbins IM, Morrow JD, Christman BW (2005) Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med 38:568-574
117. Roberts LJ II, Sweetman BJ, Payne NA, et al (1977) Metabolism of thromboxane B2 in man. Identification of the major urinary metabolite. J Biol Chem 252:7415-7417
118. Roberts LJ II, Sweetman BJ, Lewis RA, et al (1980) Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 303:1400-1404
119. RoccaB, LoebAL, Strauss JF III, et al (2000) Directed vascular expressionof the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med 6:219-221
120. Schnitzer TJ, Burmester GR, Mysler E, et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665-674
121. SchonbeckU, Sukhova GK,Graber P, et al (1999)Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155:1281-1291
122. SladekK, Sheller JR, FitzGerald GA, et al (1991) Formation of PGD2 after allergen inhalation in atopic asthmatics. Adv Prostaglandin Thromboxane Leukot Res 21A:433-436
123. Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160
124. Smyth EM, FitzGerald GA (2002) Human prostacyclin receptor. Vitam Horm 65:149-165
125. Spencer AG,Woods JW, Arakawa T, et al (1998) Subcellular localization of prostaglandin endoperoxideHsynthases- 1 and -2 byimmunoelectron microscopy. J Biol Chem 273:9886-9893
126. Spisni E, Bartolini G, Orlandi M, et al (1995) Prostacyclin (PGI2) synthase is a constitutively expressed enzyme in human endothelial cells. Exp Cell Res 219:507-513
127. Szczeklik A, Nizankowski R, Skawinski S, et al (1979) Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1:1111-1114
128. Takayama K, Garcia-Cardena G, Sukhova GK, et al (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277:44147-44154
129. Tanabe T, Yokoyama C, Miyata A, et al (1993) Molecular cloning and expression of human thromboxane synthase. J Lipid Mediat 6:139-144
130. Tanioka T, Nakatani Y, Semmyo N, et al (2000) Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275:32775-32782
131. ThomasDW,Mannon RB,Mannon PJ, et al (1998) Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 102:1994-2001
132. Thomas DW, Rocha PN, Nataraj C, et al (2003) Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J Immunol 171:6389-6395
133. Tilley SL, Audoly LP,Hicks EH, et al (1999) Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest 103:1539-1545
134. Todaka T, Yokoyama C, Yanamoto H, et al (1999) Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 30:419-426
135. Topper JN, Cai J, FalbD, et al (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 93:10417-10422
136. Tsuchiya Y, Minami I, Kadotani H, et al (2005) Resetting of peripheral circadian clock by prostaglandin E2. EMBO Rep 6:256-261
137. Ueno N, Murakami M, Tanioka T, et al (2001) Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 276:34918-34927
138. Unoki M, Furuta S, Onouchi Y, et al (2000) Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 106:440-446
139. Vezza R, Rokach J, FitzGerald GA (2001) Prostaglandin F2alpha receptor-dependent regulation of prostaglandin transport. Mol Pharmacol 59:1506-1513
140. Vielhauer GA, Fujino H, Regan JW (2004) Cloning and localization of hFP(S): a sixtransmembrane mRNA splice variant of the human FP prostanoid receptor. Arch Biochem Biophys 421:175-185
141. Wilson SJ, Roche AM, Kostetskaia E, et al (2004) Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 279:53036-53047
142. Wong D, Wang M, Cheng Y, et al (2005) Cardiovascular hazard and non-steroidal antiinflammatory drugs. Curr Opin Pharmacol 5:204-210
143. Wright DH, Metters KM, Abramovitz M, et al (1998) Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol 123:1317-1324
144. Xiao CY, Hara A, Yuhki K, et al (2001) Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104:2210-2215
145. Yu IS, Lin SR, Huang CC, et al (2004) TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 104:135-142
146. Yu Y, Fan J, Chen XS, FitzGerald GA, Funk CD (2006) Genetic model of selective COX-2 inhibition reveals novel heterodimer signalling. Nat Med (published online May 28th
147. Zhang Z, Vezza R, Plappert T, et al (2003) COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res 92:1153-1161
148. Zou M, Martin C, Ullrich V, et al (1997) Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378:707-713
149. Zucker TP, Bonisch D, Hasse A, et al (1998) Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol 345:213-220